FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891353615> ?p ?o ?g. }

• W2891353615 endingPage "5509" @default.
• W2891353615 startingPage "5509" @default.
• W2891353615 abstract "5509 Background: Most pts with EOC relapse after PDS and ct. Autologous DCVAC can present tumor antigens to elicit a durable immune response. We hypothesized that adding DCVAC to ct could improve outcomes, including progression-free survival (PFS). Methods: Key eligibility criteria were FIGO stage III EOC (serous, endometrioid, or mucinous), PS 0 - 2, post-PDS with < 1cm maximal residuum and no prior systemic therapy. We randomized pts up to 6 weeks after PDS, 1:1:1, into arm A (A; DCVAC concomitantly with ct), arm B (B; DCVAC sequentially after ct) and arm C (C; ct alone). Pts were stratified by tumor residuum (0 or < 1cm). Ct consisted of 6 cycles of carboplatin (AUC 5 - 7) and paclitaxel (175mg/m2). Pts in A and B were to receive 10 doses of DCVAC (1 × 107 DCs/dose). The primary endpoint was investigator-assessed PFS. Key secondary endpoint was overall survival (OS). Results: Between November 2013 and March 2016, 99 pts were randomized in 3 countries (A/B/C, 34/34/31). Median age was comparable in all arms (range, 61.5 - 62.0 years). The % of pts with complete cytoreduction was 85% in A and B, and 84% in C. At the planned interim analysis, the ITT population included 31 pts in A, 30 pts in B, and 31 pts in C; pts who failed leukapheresis (LP) or manufacturing were excluded. A mean of 9.6 and 9.5 doses of DCVAC were administered in A and B, respectively. Median follow-up time was 26.8 months (range, 3.24 - 43.0; 1 pt withdrew informed consent early in the trial). Median PFS was 18.3 months in A, 24.3 months in B, and 18.6 months in C. Compared to C, PFS hazard ratios (95% CI) were 1.08 (0.53 - 2.21) in A and 0.43 (0.18 - 1.03) in B. The gain in PFS in the sequential arm was statistically significant (p = 0.05), and this was supported by the same trend in OS. Median OS was not reached in any arm (14% events). There were no grade ≥ 3 adverse events (AEs) related solely to DCVAC and it did not worsen the side effects of ct. Most common LP-related AEs were mild pyrexia and moderate hypocalcemia. Conclusions: DCVAC improved PFS when administered sequentially after ct. This provides a promising maintenance treatment option delaying progression of the disease. Clinical trial information: NCT02107937." @default.
• W2891353615 created "2018-09-27" @default.
• W2891353615 creator A5003246186 @default.
• W2891353615 creator A5009523282 @default.
• W2891353615 creator A5011373942 @default.
• W2891353615 creator A5019501726 @default.
• W2891353615 creator A5021206531 @default.
• W2891353615 creator A5025445684 @default.
• W2891353615 creator A5026110870 @default.
• W2891353615 creator A5051631099 @default.
• W2891353615 creator A5061185668 @default.
• W2891353615 creator A5065943539 @default.
• W2891353615 creator A5073232598 @default.
• W2891353615 creator A5079083763 @default.
• W2891353615 date "2018-05-20" @default.
• W2891353615 modified "2023-10-18" @default.
• W2891353615 title "Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Interim analysis of a phase 2, open-label, randomized, multicenter trial." @default.
• W2891353615 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.5509" @default.
• W2891353615 hasPublicationYear "2018" @default.
• W2891353615 type Work @default.
• W2891353615 sameAs 2891353615 @default.
• W2891353615 citedByCount "5" @default.
• W2891353615 countsByYear W28913536152020 @default.
• W2891353615 countsByYear W28913536152021 @default.
• W2891353615 countsByYear W28913536152023 @default.
• W2891353615 crossrefType "journal-article" @default.
• W2891353615 hasAuthorship W2891353615A5003246186 @default.
• W2891353615 hasAuthorship W2891353615A5009523282 @default.
• W2891353615 hasAuthorship W2891353615A5011373942 @default.
• W2891353615 hasAuthorship W2891353615A5019501726 @default.
• W2891353615 hasAuthorship W2891353615A5021206531 @default.
• W2891353615 hasAuthorship W2891353615A5025445684 @default.
• W2891353615 hasAuthorship W2891353615A5026110870 @default.
• W2891353615 hasAuthorship W2891353615A5051631099 @default.
• W2891353615 hasAuthorship W2891353615A5061185668 @default.
• W2891353615 hasAuthorship W2891353615A5065943539 @default.
• W2891353615 hasAuthorship W2891353615A5073232598 @default.
• W2891353615 hasAuthorship W2891353615A5079083763 @default.
• W2891353615 hasConcept C121608353 @default.
• W2891353615 hasConcept C126322002 @default.
• W2891353615 hasConcept C141071460 @default.
• W2891353615 hasConcept C168563851 @default.
• W2891353615 hasConcept C203092338 @default.
• W2891353615 hasConcept C2776694085 @default.
• W2891353615 hasConcept C2778239845 @default.
• W2891353615 hasConcept C2780427987 @default.
• W2891353615 hasConcept C2781100745 @default.
• W2891353615 hasConcept C2781451048 @default.
• W2891353615 hasConcept C2908647359 @default.
• W2891353615 hasConcept C61943457 @default.
• W2891353615 hasConcept C71924100 @default.
• W2891353615 hasConcept C90924648 @default.
• W2891353615 hasConcept C99454951 @default.
• W2891353615 hasConceptScore W2891353615C121608353 @default.
• W2891353615 hasConceptScore W2891353615C126322002 @default.
• W2891353615 hasConceptScore W2891353615C141071460 @default.
• W2891353615 hasConceptScore W2891353615C168563851 @default.
• W2891353615 hasConceptScore W2891353615C203092338 @default.
• W2891353615 hasConceptScore W2891353615C2776694085 @default.
• W2891353615 hasConceptScore W2891353615C2778239845 @default.
• W2891353615 hasConceptScore W2891353615C2780427987 @default.
• W2891353615 hasConceptScore W2891353615C2781100745 @default.
• W2891353615 hasConceptScore W2891353615C2781451048 @default.
• W2891353615 hasConceptScore W2891353615C2908647359 @default.
• W2891353615 hasConceptScore W2891353615C61943457 @default.
• W2891353615 hasConceptScore W2891353615C71924100 @default.
• W2891353615 hasConceptScore W2891353615C90924648 @default.
• W2891353615 hasConceptScore W2891353615C99454951 @default.
• W2891353615 hasIssue "15_suppl" @default.
• W2891353615 hasLocation W28913536151 @default.
• W2891353615 hasOpenAccess W2891353615 @default.
• W2891353615 hasPrimaryLocation W28913536151 @default.
• W2891353615 hasRelatedWork W2014215628 @default.
• W2891353615 hasRelatedWork W2020778541 @default.
• W2891353615 hasRelatedWork W2075452221 @default.
• W2891353615 hasRelatedWork W2394564182 @default.
• W2891353615 hasRelatedWork W2411681602 @default.
• W2891353615 hasRelatedWork W2612460126 @default.
• W2891353615 hasRelatedWork W3114379642 @default.
• W2891353615 hasRelatedWork W4306253774 @default.
• W2891353615 hasRelatedWork W59268075 @default.
• W2891353615 hasRelatedWork W2183318930 @default.
• W2891353615 hasVolume "36" @default.
• W2891353615 isParatext "false" @default.
• W2891353615 isRetracted "false" @default.
• W2891353615 magId "2891353615" @default.
• W2891353615 workType "article" @default.